BioTech Health XMay 31, 2023 Biotech NewsMerck Announces Failure in Keytruda Head and Neck Cancer Phase 3 Clinical Trial 3 minute read Today Merck & Co. (NYSE: MRK) announced that Keytruda has failed the Phase 3 clinical trial KEYNOTE-412 evaluating… 0 Shares 0 0 0 0 0 0 0